Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Myasthenia Gravis
Pharma
Argenx telegraphs CEO switch as chief drug Vyvgart rolls ahead
Karen Massey, who joined the Amsterdam-based immunology specialist as chief operating officer in early 2023, is now set to assume the role of CEO.
Fraiser Kansteiner
Jan 5, 2026 2:12pm
Amgen nabs FDA nod for Uplizna in generalized myasthenia gravis
Dec 12, 2025 9:49am
Argenx lays out details on Vyvgart's seronegative gMG win
Oct 29, 2025 2:34pm
J&J's Imaavy comes up short in rheumatoid arthritis study
Aug 29, 2025 10:56am
Argenx pursues Vyvgart nod in seronegative myasthenia gravis
Aug 25, 2025 11:38am
Argenx serves up Seles collab for myasthenia gravis awareness
Aug 12, 2025 7:00am
